Investment analysts and portfolio managers look into their crystal balls to predict the best-performing stocks for the year ahead.
A higher price for Pacific Edge’s Cxbladder Triage Plus test has pushed up its share price and forecast profitability, Jarden analyst says.
Her long tenure on the board has been the subject of speculation in the investment community recently.
The goal of near-doubling revenue within five years follows a forecast dip in revenue for FY25.
However, the retailer’s boss says any drawdown will be ‘petty cash’ for the company.
Large format retail investor has increased its debt headroom by $100m to fund the purchase, with an offer to raise up to $62.5m in convertible notes.
Firm sees investment company attractively priced with opportunities for its datacentre and US energy holdings.
Executives forfeit short-term incentives ‘in light of the group’s poor financial performance’.
The company is trading at a record-high multiple, analysts say.
Chair David Kirk says the company is materially undervalued.
